Edmund Harrigan
Director/Board Member at ACADIA PHARMACEUTICALS INC.
Net worth: 1 M $ as of 30/03/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stephen Davis | M | 63 | 10 years | |
| Julian Baker | M | 57 | 23 years | |
| Stéphane Thiroloix | M | - |
Algotherapeutix SAS
 Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | 6 years |
| Clay Thorp | M | 55 | 22 years | |
| Herve Hoppenot | M | 64 | 10 years | |
| Stephen Biggar | M | 53 | 11 years | |
| Jason Brown | M | 37 | 6 years | |
| Jennifer J. Rhodes | F | 53 | 7 years | |
| Mark Schneyer | M | 50 | 13 years | |
| Jonathan Mow | M | 59 | 12 years | |
| Nancy Hutson | M | 74 | 32 years | |
| Susanne Antonie Schaffert | M | 57 | 2 years | |
| Susan Arnold | M | 49 | 14 years | |
| Joseph Echevarria | M | 66 | 9 years | |
| Albert Kildani | M | - | 1 years | |
| Alexander Sapir | M | 57 | 4 years | |
| Katherine High | M | 72 | 4 years | |
| Bob Mischler | M | - | 9 years | |
| Pablo Cagnoni | M | 60 | 1 years | |
| Kristopher Hanson | M | 52 | 5 years | |
| Elizabeth Garofalo | M | 66 | 4 years | |
| Lawrence Perkins | M | 47 | 2 years | |
| Brendan Teehan | M | 56 | 6 years | |
| Julie Fisher | F | - | 6 years | |
| Thomas Tray | M | 46 | 19 years | |
| James Daly | M | 63 | 8 years | |
| Scott A. Byrd | M | 54 |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | - |
| Katherine Bishop | M | 58 | 3 years | |
| Laura Brege | F | 66 | 16 years | |
| Sally Susman | F | 62 | 17 years | |
| Jean-Jacques Bienaimé | M | 70 | 9 years | |
| Shantanu Narayen | M | 60 | 11 years | |
| Otis Brawley | M | 64 | 3 years | |
| Don Soland | M | 65 | 9 years | |
| Helen Hobbs | M | 71 | 13 years | |
| Sheila Denton | F | 58 | 1 years | |
| Jacqualyn Fouse | M | 62 | 7 years | |
| William Humphries | M | 57 | 3 years | |
| Jim Smith | M | 64 | 10 years | |
| Paul Clancy | M | 62 | 9 years | |
| Suzanne Johnson | F | 66 | 17 years | |
| Richard van den Broek | M | 57 | 5 years | |
| Peter Langmuir | M | - | 9 years | |
| Michael Morrissey | M | - | 8 years | |
| Lothar H. Finke | M | - | 7 years | |
| James Kihara | M | - | 4 years | |
| Catalina Loveman | F | - | 9 years | |
| Barbara Dalton | M | 69 | 17 years | |
| Thibaut Roulon | M | - |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | - |
| Barry Flannelly | M | 66 | 10 years | |
| Kimberly Manhard | F | 64 | - | |
| Holly Valdiviez | F | - | 2 years | |
| Sanjeev Pathak | M | - | 3 years | |
| Kevin Oliver | M | - | 1 years | |
| Benir Ruano | M | - | 2 years | |
| Ponni Subbiah | M | - | 5 years | |
| Parag V. Meswani | M | - | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jeffrey Kindler | M | 68 | 8 years | |
| Henry McKinnell | M | 81 | 8 years | |
| Steven Paul | M | 73 | 6 years | |
| Eric Elenko | M | 51 | 10 years | |
| William Steere | M | 87 | 28 years | |
| Alan Musso | M | 62 | 4 years | |
| Atul Pande | M | 69 | 8 years | |
| Paul Friedman | M | 81 | 20 years | |
| Elena Ridloff | F | 44 | 3 years | |
| Christopher Coughlin | M | 71 | 4 years | |
| David Shedlarz | M | 75 | 31 years | |
| Amy Schulman | F | 63 | 6 years | |
| Dennis Ausiello | M | 78 | 13 years | |
| George A. Lorch | M | 82 | 15 years | |
| Martin MacKay | M | 68 | 14 years | |
| Todd Young | M | 52 | 2 years | |
| Shane Ward | M | 49 | 2 years | |
| Everett Cunningham | M | 57 | 9 years | |
| Gregory S. Naeve | M | 60 | 8 years | |
| Jacob M. Plotsker | M | 56 | 16 years | |
| Glenn F. Baity | M | 54 | 14 years | |
| Peter Klein | M | 46 | 12 years | |
| Paul Fitzhenry | M | 63 | 4 years | |
| Frank B. McGuyer | M | 72 | 9 years | |
| David M. Spencer | M | 61 | 15 years | |
| Austin Kim | M | 60 | 6 years | |
| Caroline Loewy | F | 58 | 5 years | |
| John P. Sharp | M | 59 | 6 years | |
| Mace Rothenberg | M | 67 | 13 years | |
| Olivier Jean Bohuon | M | 65 |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | 6 years |
| Alan Levin | M | 62 | 20 years | |
| Leslie L. Iversen | M | 86 | 18 years | |
| Stephen W. Sanger | M | 78 | 9 years | |
| Peter Corr | M | 76 | 6 years | |
| Michael Brown | M | 82 | 16 years | |
| Robert N. Burt | M | 86 | 11 years | |
| James Kilts | M | 76 | 13 years | |
| Frances Fergusson | M | 79 | 9 years | |
| Freda Lewis-Hall | M | 69 | 11 years | |
| Srdjan Stankovic | M | 67 | 7 years | |
| Michael R. Jirousek | M | 65 | 5 years | |
| Mary Gray | M | 71 | 11 years | |
| Amanda Morgan | F | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 96 | 96.00% |
| France | 4 | 4.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Edmund Harrigan
- Personal Network
